SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 205.510.0%10:15 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (15071)2/14/1998 1:09:00 PM
From: Andrew H  Read Replies (4) of 32384
 
While it is a long way from rats to people (despite Bernie's apparent predilections), one would think the recent news would have been good for more than a skimpy one point jump. If tamoxifen pulls in 560MM a year, then it is not much of a leap to envision LGND's revenues going up substantially when Targretin comes to market in the first part of 1999. Of course it depends on preliminary P2 results, but these ought to be available by the time Targretin gets FDA approval. My guess is that they will start a couple of trials very soon--Targretin as monotherapy and Targretin in combination with Tamoxifen. Good results for either will result in a lot of off label prescriptions for Targretin, IMO.

If this scenario pans out, LGND could earn a LOT more than .09/share in 1999.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext